Holen Sie sich die Stockscreener-App
6.69
2.21%
0.13
Handel nachbörslich:
6.70
0.010
+0.15%
Schlusskurs vom Vortag:
$6.56
Offen:
$6.61
24-Stunden-Volumen:
466.91K
Relative Volume:
1.34
Marktkapitalisierung:
$259.71M
Einnahmen:
$25.42M
Nettoeinkommen (Verlust:
$-143.75M
KGV:
-1.9275
EPS:
-3.4709
Netto-Cashflow:
$-129.55M
1W Leistung:
+18.67%
1M Leistung:
-46.91%
6M Leistung:
-33.48%
1J Leistung:
-10.60%
1-Tages-Spanne:
$6.325
$6.84
1-Wochen-Bereich:
$5.70
$6.84
52-Wochen-Spanne:
$4.93
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
6.69 | 254.66M | 25.42M | -143.75M | -129.55M | -3.4709 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-11 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Entrada Therapeutics clinical trial data sparks brutal stock selloffhere's why - MSN
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TRDA - Finviz
Insider Move at Entrada Therapeutics Sparks Fresh Investor Interest - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Entrada Thera - The National Law Review
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock By Investing.com - Investing.com Australia
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock - Investing.com
Entrada Therapeutics (TRDA) director’s trust buys 5,000 common shares - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutic - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
User - The Chronicle-Journal
Entrada Therapeutics Reports Positive Phase 1/2 Results for ENTR-601-44 in Duchenne Muscular Dystrophy, Highlighting Best-in-Class Potential and $5B U.S. Market Opportunity 679 - Minichart
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress - TipRanks
Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026 - TradingView
Entrada Therapeutics (TRDA) furnishes updated corporate presentation to investors - Stock Titan
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review
INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC - GlobeNewswire
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Scott Coop
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
(TRDA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Entrada Therapeutics faces investigation after drug trial results disappoint, stock plunges 57%. - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc.TRDA - PR Newswire
Entrada Therapeutics, Inc. Common Stock (TRDA) Stock Price Today & Analysis - Gotrade
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
HC Wainwright Has Positive Estimate for TRDA Q2 Earnings - MarketBeat
TradingKey - TradingKey
Investors in Entrada Therapeutics urged to join probe after stock drops on clinical trial results - Pluang
Entrada Therapeutics, Inc. Shareholders Are Encouraged to - GlobeNewswire
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
MSN Money - MSN
Transcript : Entrada Therapeutics, Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile - Barchart.com
Entrada Therapeutics, Inc.Common Stock (NQ: TRDA - FinancialContent
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock SelloffHere's Why - Sahm
Entrada Therapeutics Cut to Neutral From Buy by HC Wainwright & Co. - Moomoo
This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga
H.C. Wainwright Downgrades Entrada Therapeutics(TRDA.US) to Hold Rating - Moomoo
Entrada’s stock drops as DMD drug’s efficacy falls short - Yahoo Finance
Entrada Therapeutics Declines on Duchenne Muscular Dystrophy Study Data -- Update - Moomoo
Entrada’s ENTR-601-44 Shows Efficacy, But Dystrophin Raises Questions - Citeline News & Insights
Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Entrada sinks on mixed DMD data with ENTR-601-44 - BioWorld News
Entrada Therapeutics Announces Positive Topline Results from Coho - The National Law Review
Entrada plunges on trial data for Duchenne drug (TRDA:NASDAQ) - Seeking Alpha
Entrada shares sink after Duchenne drug falls short of expectations - WHTC
Entrada Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Entrada Therapeutics Inc-Aktie (TRDA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sethuraman Natarajan | President, Research & Develop. |
May 04 '26 |
Sale |
15.39 |
25,907 |
398,810 |
216,317 |
| Dowden Nathan J | President & COO |
May 04 '26 |
Option Exercise |
1.74 |
15,000 |
26,100 |
213,588 |
| Dowden Nathan J | President & COO |
May 04 '26 |
Sale |
15.33 |
15,000 |
229,953 |
198,588 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):